左乙拉西坦
医学
癫痫
临床试验
神经科学
药理学
内科学
心理学
精神科
摘要
UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.
科研通智能强力驱动
Strongly Powered by AbleSci AI